On Nov 01, major Wall Street analysts update their ratings for $IQVIA Holdings (IQV.US)$, with price targets ranging from $235 to $270.
BofA Securities analyst Michael Ryskin maintains with a buy rating, and adjusts the target price from $260 to $255.
Barclays analyst Luke Sergott maintains with a buy rating, and adjusts the target price from $260 to $255.
Evercore analyst Elizabeth Anderson CFA maintains with a buy rating, and adjusts the target price from $265 to $235.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and maintains the target price at $255.
Mizuho Securities analyst Ann Hynes maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
The market's stability was noted by the company, while issues with bookings were attributed to delays and drug failures rather than significant effects from pipeline rationalization.
The company has been navigating a difficult industry operating landscape. Commentary from the company indicates that the pharmaceutical portfolio adjustments related to the IRA may be concluding, and the company seems poised to benefit from the pharmaceutical industry's trend towards vendor consolidation.
Iqvia's recent financial performance surpassed consensus expectations in total revenue, adjusted EBITDA, and adjusted EPS. However, the company has revised its 2024 guidance downwards for all metrics. This revision is attributed to the challenges posed by the Inflation Reduction Act and broader economic factors. Additionally, the guidance for R&DS has been impacted by the delay and cancellation of two significant trials.
Concerns are being raised about near-term CRO marketplace dynamics. With a significant portion of the company experiencing a slow or weakening trend, there are questions about whether the improving segment will do more than just maintain equilibrium.
Here are the latest investment ratings and price targets for $IQVIA Holdings (IQV.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
